CoChat

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Open access
Pal, Sumanta K., McGregor, Bradley, Suárez, Cristina, Tsao, Che-Kai, Kelly, William, Vaishampayan, Ulka, Pagliaro, Lance, Maughan, Benjamin L., Loriot, Yohann, Castellano, Daniel, Srinivas, Sandy, McKay, Rana R., Dreicer, Robert, Hutson, Thomas, Dubey, Sarita, Werneke, Scott, Panneerselvam, Ashok, Curran, Dominic, Scheffold, Christian, Choueiri, Toni K., Agarwal, Neeraj · 2021 · Journal of Clinical Oncology
Cited by 140

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

PURPOSE: COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid tumors. We report results from patients with advanced clear cell (cc) and non–clear cell (ncc) renal cell carcinoma (RCC). METHODS: This phase Ib study ( NCT03170960 ) enrolled patients age ≥ 18 years with advanced RCC. A dose-escalation stage was followed by expansion cohorts. For cohort expansion, prior systemic therapy was not permitted for ccRCC but allowed for nccRCC. Patients received oral cabozantinib 40 mg once a day (ccRCC and nccRCC) or 60 mg once a day (ccRCC only) plus atezolizumab (1,200 mg intravenously, once every 3 weeks). The primary end point was investigator-assessed objective response rate (ORR) per RECIST v1.1; the secondary end point was safety. RESULTS: A total of 102 patients were enrolled. Median follow-up was 25.8, 15.3, and 13.3 months for the 40-mg ccRCC, 60-mg ccRCC, and nccRCC groups, respectively. ORR was 53% (80% CI, 41 to 65) in the 40-mg ccRCC group (n = 34) and 58% (80% CI, 46 to 70) in the 60-mg ccRCC group (n = 36), 3% and 11%, respectively, with complete response; median progression-free survival (exploratory end point) was 19.5 and 15.1 months, respectively. In nccRCC (n = 32), ORR was 31% (80% CI, 20 to 44), all partial responses; median progression-free survival was 9.5 months. Grade 3 or 4 treatment-related adverse events (TRAEs) were reported by 71% of patients in the 40-mg ccRCC group, 67% in the 60-mg ccRCC group, and 38% in the nccRCC group; TRAEs leading to discontinuation of both agents occurred in 15%, 6%, and 3% of patients, respectively. There were no grade 5 TRAEs. CONCLUSION: The novel combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity and acceptable tolerability in patients with advanced ccRCC and nccRCC. Disease control was observed across dose levels and histologic subtypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.00939

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 140

Metadata

Authors
Pal, S. K., McGregor, B., Suárez, C., Tsao, C.-K., Kelly, W., Vaishampayan, U., Pagliaro, L., Maughan, B. L., Loriot, Y., Castellano, D., Srinivas, S., McKay, R. R., Dreicer, R., Hutson, T., Dubey, S., Werneke, S., Panneerselvam, A., Curran, D., Scheffold, C., Choueiri, T. K., & Agarwal, N.
Venue
Journal of Clinical Oncology
Published
2021-11-20
Volume
39
Issue
33
Pages
3725-3736
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3197818039
Cited by
140
References
5
FWCI
15.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. https://app.cochat.ai/papers/10.1200/jco.21.00939
The paper
Pal, S. K., McGregor, B., Suárez, C., Tsao, C.-K., Kelly, W., Vaishampayan, U., Pagliaro, L., Maughan, B. L., Loriot, Y., Castellano, D., Srinivas, S., McKay, R. R., Dreicer, R., Hutson, T., Dubey, S., Werneke, S., Panneerselvam, A., Curran, D., Scheffold, C., . . . Agarwal, N. (2021). Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.00939

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.